Such Pin1 inhibitors that reduce Pin activity would not be directly applicable to treat AD because Pin1 deficiency contributes to AD, and Pin1 expression is inversely correlated with tauopathy and AD [230]. The gene discussed is DYNLL1; the disease is tauopathy.